FDD Analysis Report

ARCpoint Labs

ARCpoint Franchise Group, LLC

FDD Year: 2026Current
Analysis Date: September 10, 2026

Key Metrics At-a-Glance

Franchise Fee

See FDD

Total Investment

See FDD

Royalty

See FDD

of gross sales

Brand Fund

See FDD

of gross sales

Initial Term

See FDD

System Size

213 units

Avg Revenue

N/A

Not disclosed

About This Franchise

# ARCpoint Labs Franchise Intelligence Report

## Executive Summary

ARCpoint Labs is a diagnostic testing franchise serving employers, healthcare providers, and individuals. The $201K-$362K investment provides entry to a $30B+ testing industry. With 138 locations and #1 Entrepreneur ranking in lab testing, ARCpoint offers a B2B-focused healthcare services model. Top performers differentiate through clinical testing mix and higher-margin testing modalities.

## The Business

ARCpoint Labs provides drug testing, DNA testing, clinical lab work, and wellness testing. Primary customers are employers requiring pre-employment, random, and post-accident drug testing. The franchise also serves healthcare providers, attorneys, individuals, and third-party administrators (TPAs). Franchisees manage the lab operation and sales relationships while actual testing is performed through partner laboratories. Founded in 2005, franchising since 2006.

## The Numbers

- **Total Investment**: $200,800 - $361,720 - **Franchise Fee**: $54,500 - **Royalty**: 7% of gross sales (minimum $350/month) - **Brand Fund**: 2% (minimum $100/month) - **Liquid Capital Required**: $100,000 - **Net Worth Required**: $400,000 - **Credit Score**: 710+ required - **Veteran Discount**: $5,000 off training fee - **Contract Term**: 10 years with 10-year renewal - **Units**: 138 in 27 states

## System Health

Healthy and growing. The network has expanded to 138 locations across 27 states, with the South representing the largest region (84 units). The testing industry continues growing driven by employer compliance requirements, healthcare integration, and new testing modalities. Being franchising since 2006 (19 years) demonstrates concept durability through multiple economic cycles.

## Franchisee Experience

**Positive feedback:** - "I love running my own business and I appreciate the support I've received from both the franchise HQ as well as other franchisees." - Franchisees report becoming "local experts" and creating profitable operations - Strong peer support network

**Top performer characteristics:** - Higher mix of clinical testing - Non-traditional modalities (oral fluid, hair, nail testing) with higher margins - Less dependence on TPA collection accounts (13% vs 27% for bottom performers)

**Training program:** - Online training, orientation, in-person training, owner learning - Operations team site visit within 30 days of opening - System-wide meetings every 1-2 years

## Risk Assessment

**MODERATE**: High royalty rate - 7% is above average for service franchises

**MODERATE**: Sales-dependent - B2B sales to employers requires consistent business development

**MODERATE**: Healthcare regulations - compliance requirements can be complex

**LOW**: Recession resistance - drug testing is often mandated regardless of economic conditions

**LOW**: Industry tailwinds - testing market continues expanding with new modalities

## Competitive Position

ARCpoint was ranked #1 in lab/testing space by Entrepreneur (#120 overall in 2017). The franchise competes with Quest Diagnostics, LabCorp (national labs), independent testing centers, and hospital-based labs. ARCpoint differentiates through:

- Local service and relationship focus - Fast turnaround times - Convenient locations - Multi-modality testing capabilities - Direct employer relationships

The B2B model provides recurring revenue from established employer accounts.

## Validation Questions

1. What percentage of revenue comes from recurring employer accounts vs one-time tests? 2. How long does it typically take to build an employer client base? 3. What's your mix between drug testing, clinical, and DNA testing? 4. How has the shift to remote work affected employer drug testing demand? 5. What differentiates successful locations from struggling ones? 6. How do you compete with Quest and LabCorp for employer accounts? 7. What's the typical gross margin on different testing types?

## Data Gaps

- Specific Item 19 financial performance data not publicly available - Average revenue per location not disclosed - Franchisee turnover and closure rates not specified - Gross margin by testing type not detailed - Geographic market saturation not analyzed

## Verdict: MODERATE-STRONG

ARCpoint offers entry to a growing healthcare testing market with a proven franchise model. The B2B focus provides recurring revenue potential, and the #1 category ranking demonstrates brand strength. The 7% royalty is high but offset by the essential nature of employer drug testing. Best suited for sales-oriented operators comfortable with B2B relationship building and healthcare compliance.

Ongoing Fees

Fee TypeAmountNotes
RoyaltySee FDD of Gross Revenue-
Brand FundSee FDD of Gross Revenue-

Item 19: Financial Performance Representations

No Financial Performance Representations

This franchisor does not provide Item 19 financial performance representations. Approximately 35% of franchisors choose to disclose this information.

Recommendation: Request financial information directly from existing franchisees listed in Exhibit I during your due diligence. Contact 10-15 franchisees to gather revenue and profitability data before making an investment decision.

Learn more about Item 19 disclosures →

Risk Assessment

Items to Review

No notable items identified

Positive Indicators

Review FDD for positive factors

Due Diligence Recommendations

P1

Contact 10-15 existing franchisees to gather operational and financial insights

Franchisee interviews are the most valuable source of information about day-to-day operations and realistic financial expectations.

P2

Have a franchise attorney review the Franchise Agreement

Professional legal review can identify unfavorable terms and potential negotiation points.

P3

Research local market conditions and competition

Understanding your specific market is essential for success, regardless of system-wide performance.

Download Complete FDD

Access the full Franchise Disclosure Document including all 23 items, exhibits, and financial statements.

Browse Similar Franchises

Learn More About FDDs

New to franchise investing? Our educational guides will help you understand what to look for in the ARCpoint Labs FDD.

About ARCpoint Labs Franchise

ARCpoint Labs is a franchise that offers entrepreneurs the opportunity to own and operate their own business within an established system. As of the 2026 Franchise Disclosure Document, the system has grown to 213 locations across the United States. This analysis provides prospective franchisees with key insights from the FDD to support informed investment decisions.

ARCpoint Labs Franchise Cost

The total initial investment required to open a ARCpoint Labs franchise ranges from See FDD for details. This investment includes the initial franchise fee of See FDD for details, along with expenses for real estate, equipment, inventory, training, and working capital to sustain operations during the initial period. Ongoing fees include a royalty fee of See FDD of gross sales. Prospective franchisees should review Item 7 of the FDD for a complete breakdown of estimated initial investment costs.

ARCpoint Labs Item 19 Financial Performance

ARCpoint Labs does not provide financial performance representations in Item 19 of their FDD. Approximately 35% of franchisors choose to disclose this information. Without franchisor-provided financial data, prospective franchisees should contact existing franchisees directly to gather information about revenue, expenses, and profitability. The franchisee contact list in Exhibit I provides names and contact information for current and former franchise owners.

ARCpoint Labs Franchise Growth and System Health

The ARCpoint Labs franchise system has shown stable performance based on unit count data from Item 20 of the FDD. Prospective franchisees should examine the historical data on unit openings, closings, and transfers to understand the system's trajectory and identify any concerning trends.

ARCpoint Labs Franchise Investment Considerations

The ARCpoint Labs FDD contains important disclosures that prospective franchisees should carefully review before making an investment decision. Key factors to evaluate include the franchise fee structure, ongoing royalty requirements, territory rights, termination history, and franchisor support systems. Every franchise investment carries risk, and this analysis should be combined with professional legal and financial advice. Review the complete FDD and speak with current franchisees to gain a comprehensive understanding of the opportunity.

Due Diligence Recommendations for ARCpoint Labs

Before investing in a ARCpoint Labs franchise, prospective franchisees should:

  • Contact multiple existing franchisees to gather operational and financial insights
  • Have a franchise attorney review the Franchise Agreement and all exhibits
  • Research local market conditions and competitive landscape
  • Develop a detailed business plan with realistic financial projections
  • Verify all information provided by the franchisor independently

Download the ARCpoint Labs FDD

Access the complete ARCpoint Labs Franchise Disclosure Document, including all 23 Items, exhibits, franchise agreement, and audited financial statements. FreeFDDs provides free access to FDDs to promote franchise transparency and help prospective franchisees make informed decisions. The FDD contains critical information that should be reviewed in its entirety before making any investment decision.

Disclaimer

This analysis report is provided for informational purposes only. The data presented has been extracted from the Franchise Disclosure Document and may contain errors or omissions.

Prospective franchisees should conduct their own due diligence, review the complete FDD document, and consult with qualified legal and financial advisors before making any investment decisions.